IDEAYA Biosciences (IDYA) Net Income towards Common Stockholders (2018 - 2026)
IDEAYA Biosciences (IDYA) posted Net Income towards Common Stockholders of -$232.8 million for Q1 2026, down 147.48% sequentially from -$94.1 million in Q4 2025, and down 149.92% YoY from $466.3 million in Q1 2025.
Powered by 
Analysis
IDEAYA Biosciences (IDYA) Net Income towards Common Stockholders (2018 - 2026) Analysis & Trends
IDEAYA Biosciences has reported Net Income towards Common Stockholders for 9 years, with the latest figure at -$232.8 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 149.92% year-over-year to -$232.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$432.1 million (up 19.4% YoY) and the FY2025 annual result came in at -$354.3 million, up 27.94% from the prior year.
- Net Income towards Common Stockholders slipped to -$232.8 million in Q1 2026 per IDYA's latest filing, from -$94.1 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $30.2 million in Q3 2025 and troughed at -$232.8 million in Q1 2026.
- A 5-year average of -$74.2 million and a median of -$39.2 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders plunged 379.35% in 2024, then soared 122.45% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at -$25.3 million in 2022, then tumbled by 54.68% to -$39.2 million in 2023, then tumbled by 275.66% to -$147.2 million in 2024, then surged by 36.09% to -$94.1 million in 2025, then sank by 147.48% to -$232.8 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$232.8 million, -$94.1 million, and $30.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -13.27 Mn |
| 10 | IDEAYA Biosciences | 3.66 Bn | 2.83 Bn | - | -123.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -123.47 Mn |
| Mar 31, 2026 | -111.31 Mn |
| Dec 31, 2025 | -94.36 Mn |
| Sep 30, 2025 | 108.98 Mn |
| Jun 30, 2025 | -88.87 Mn |
| Mar 31, 2025 | -83.62 Mn |
| Dec 31, 2024 | -147.16 Mn |
| Sep 30, 2024 | -61.64 Mn |
| Jun 30, 2024 | -65.42 Mn |
| Mar 31, 2024 | -52.50 Mn |
| Dec 31, 2023 | -40.61 Mn |
| Sep 30, 2023 | -33.10 Mn |
| Jun 30, 2023 | -32.48 Mn |
| Mar 31, 2023 | -24.81 Mn |
| Dec 31, 2022 | -25.31 Mn |
| Sep 30, 2022 | 287,000.00 |
| Jun 30, 2022 | -23.32 Mn |
| Mar 31, 2022 | -16.31 Mn |
| Dec 31, 2021 | -19.03 Mn |
| Sep 30, 2021 | -11.76 Mn |